JAK Inhibitors: The Newest Class of Psoriasis Treatment

A new class of oral psoriasis medication has emerged in recent years — TYK2 inhibitors, a more targeted cousin of JAK inhibitors — offering pill-based treatment with a distinct safety profile from older systemic options. Here's what the trial data actually shows.

What Makes This Class Different

Deucravacitinib, an oral, selective TYK2 (tyrosine kinase 2) inhibitor, was approved by the FDA in September 2022 for adults with moderate-to-severe plaque psoriasis — the first drug in its specific class. TYK2 inhibitors work by blocking signaling for IL-23, IL-12, and type I interferon — key cytokines in psoriasis's underlying immune pathway — through a distinct allosteric mechanism that differentiates it from broader JAK1/2/3 inhibitors used for other inflammatory conditions. This selectivity is the headline feature: it targets the specific pathway relevant to psoriasis while largely sparing other JAK-related signaling, which appears to translate into a different, generally milder side-effect profile than broader JAK inhibitors.

The Clinical Trial Evidence

Deucravacitinib's approval was based on two large phase III trials (POETYK PSO-1 and PSO-2), involving more than 1,600 patients with moderate-to-severe plaque psoriasis, comparing it against both placebo and apremilast (an existing oral treatment). A 2023 meta-analysis of the available randomized controlled trial data confirmed deucravacitinib showed consistent clinical efficacy across all phase II and III trials, with significant PASI-75 and Physician's Global Assessment improvements compared to both placebo and apremilast at week 16.

A separate phase 3b/4 trial specifically for scalp psoriasis (PSORIATYK SCALP) — a notoriously hard-to-treat presentation — found meaningful improvement by week 16 using scalp-specific severity measures, in a placebo-controlled design.

Evidence in Psoriatic Arthritis Too

A phase II trial in psoriatic arthritis found deucravacitinib significantly outperformed placebo on ACR-20 response (a standard arthritis improvement measure) — 52.9% and 62.7% response at the two doses tested, versus 31.8% for placebo — alongside significant PASI-75 improvement in the same patients. Notably, the trial reported no serious adverse events, and no cases of herpes zoster or major cardiovascular events — a reassuring early safety signal, though the researchers themselves noted that larger, longer trials are needed to fully confirm the safety profile.

Why This Matters for Patients

• It's an oral pill, not an injection — a genuine convenience advantage over many biologics for people who prefer to avoid injections
• Its safety profile so far appears more favorable than broader JAK inhibitors, attributed to its more selective mechanism, though long-term data is still accumulating
• It offers another option for people who haven't responded well to other treatments, or who prefer oral to injectable medication

Frequently Asked Questions

Is deucravacitinib the same as a biologic?

No — biologics are injectable proteins targeting specific immune molecules directly, while deucravacitinib is a small-molecule oral pill that works inside cells to block a signaling pathway. Different mechanism, similar underlying goal.

How does this compare to older JAK inhibitors?

Deucravacitinib's more selective TYK2-specific mechanism is generally considered to produce a different, often milder side-effect profile than broader JAK1/2/3 inhibitors, though your dermatologist can advise on what's most appropriate for your specific situation.

Next Steps

For a broader look at treatment timelines across drug classes, see our full article on how long psoriasis treatment takes to work.

This article is for general educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Discuss whether this medication class is appropriate for you with your dermatologist.

Sources & References

• Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis. PubMed
• The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis. PMC10570425
• Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. PMC9120409